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Abstract: Purpose  The REIC (Reduced expression in immortalized cells)/Dkk-3 gene is down-
regulated in various cancers and considered to be a tumor suppressor gene.
REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a
major transcript in various cancer cells and its promoter activity was much stronger
than that of type-b. In this study, we examined the methylation status of REIC/Dkk-3
type-a in a broad range of human malignancies.
Methods  We examined the REIC/Dkk-3 type-a methylation in breast cancers, non-
small cell lung cancers(NSCLCs), gastric cancers and colorectal cancers, and
malignant pleural mesotheliomas (MPMs) using a quantitative combined bisulfite
restriction analysis (qCOBRA) assay and bisulfate sequencing. REIC/Dkk-3 type-a
expression was examined using reverse-transcriptional PCR. The relationships
between the methylation and clinicopathological factors were then analyzed.
Results  The rate of REIC/Dkk-3 type-a methylation ranged from 26.2% to 50.0% in the
various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast
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cancer cell lines was significantly heavier than that in the other cell lines that we tested.
REIC/Dkk-3 type-a methylation was inversely correlated with the expression of
REIC/Dkk-3. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using
5-aza-2'-deoxycytidine treatment. We found that estrogen receptor (ER)-positive breast
cancers were significantly more common among the methylated group than among the
non-methylated group.
Conclusions  REIC/Dkk-3 type-a methylation was frequently detected in a broad range
of cancers, including breast cancers, NSCLCs, MPMs, gastric cancers and colon
cancers, and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in
these malignancies.
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Abstract 
Purpose  The REIC (Reduced expression in immortalized cells)/Dkk-3 is down-regulated in various 
cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). 
REIC type-a mRNA has shown to be a major transcript in various cancer cells and its promoter activity 
was much stronger than that of type-b. In this study, we examined the methylation status of REIC/Dkk-3 
type-a in a broad range of human malignancies. 
Methods  We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small cell lung cancers 
(NSCLCs), gastric cancers and colorectal cancers, and malignant pleural mesotheliomas using a 
quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a 
and type-b expression was examined using reverse-transcriptional PCR. The relationships between the 
methylation and clinicopathological factors were analyzed.  
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Results  The rate of REIC/Dkk-3 type-a methylation ranged from 26.2% to 50.0% in the various primary 
tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly 
heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely 
correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and 
type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 
5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were 
significantly more common among the methylated group than among the non-methylated group.  
Conclusions  REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and 
appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.  
 
Keywords   DNA methylation - REIC/Dkk-3 - breast cancer - lung cancer - mesothelioma 
 
Introduction 
Accumulating evidence suggests that tumor progression is governed not only by genetic changes intrinsic 
to cancer cells but also by epigenetic changes. In cancer epigenetics, aberrant CpG methylation in the 
promoter region is a key mechanism for gene inactivation resulting in tumorigenesis in human 
malignancies (Toyooka et al. 2004).   
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The REIC (Reduced expression in immortalized cells)/Dkk-3(Dickkopf-3) cDNA, which was 
expressed in human normal cells and was down-regulated in human immortalized cells and human 
tumor-derived cells, was identified using a representative difference analysis system (Tsuji et al. 2000). 
The amino acid sequence revealed that the REIC gene product was human Dkk-3, one of the Dkk family 
members. The Dkk family of secreted proteins consists of four members, which share two conserved 
cysteine-rich domains (Glinka et al. 1998; Krupnik et al. 1999). Dkk-1, the best-characterized member of 
the Dkk family, functions as a Wnt antagonist or agonist by binding to and inhibiting or activating the 
Wnt coreceptor LRP6 (Bafico et al. 2001). Unlike Dkk-1, Dkk-2, and Dkk-4, however, REIC/Dkk-3 was 
recently shown to inhibit TCF-4 receptor activity in lung cancer cells (Yue et al. 2008). TCF-4 activates 
c-Myc and cyclinD1 through the Wnt/beta-catenin pathway and promotes tumor invasion and metastasis. 
Because REIC/Dkk-3 is down-regulated in a variety of malignancies and the overexpression of 
REIC/Dkk-3 suppresses cell growth, REIC/Dkk-3 has been proposed to act as a tumor suppressor (Tsuji et 
al. 2001; Kurose et al. 2004). Hypermethylation and the down-regulation of REIC/Dkk-3 were observed 
in a variety of malignancies including non-small cell lung cancers (NSCLCs) (Kobayashi et al. 2002; 
Licchesi et al. 2008), gastrointestinal cancers (Maehata et al. 2008), renal clear cell carcinoma (Kurose et 
al. 2004), acute lymphoblastic leukemia (Roman-Gomez et al. 2004) and osteosarcomas (Hoang et al. 
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2004). We previously showed the therapeutic effect of REIC/Dkk-3 in prostate cancers (Abarzua et al. 
2005; Edamura et al. 2007) and malignant pleural mesothelioma (MPM) (Kashiwakura et al. 2008). In 
addition, tumor suppression by REIC/Dkk-3 has also been confirmed in other malignant tumors (Hsieh et 
al. 2004; Hoang et al. 2004).  
REIC/Dkk-3 mRNA has two isoforms (type-a,b; GeneBank accession AB057804). Many papers 
have described the methylation status in the promoter of REIC/Dkk-3 type-b (Licchesi et al. 2008; 
Maehata et al. 2008; Veeck et al. 2009). However, the promoter of REIC/Dkk-3 type-a also seems to be 
important, since Kobayashi et al. (2002) (the group that first identified the REIC/Dkk-3 in immortalized 
cells) have demonstrated that the promoter activity of REIC/Dkk-3 type-a (major promoter) had an 
approximately 26-fold stronger effect than that of REIC/Dkk-3 type-b (minor promoter) in a luciferase 
assay and major transcript was REIC/Dkk-3 type-a in various cancer cell they tested. They suggested that 
hypermethylation of the major promoter (type-a) was a major mechanism for down-regulation of REIC 
expression. They also suggested the methylation of the minor promoter (type-b) was accompanied with 
that of major promoter (type-a) in most case except four lung cancer cells that they tested. Regardless 
those four lung cancer cells had type-b hypermethylation, REIC/Dkk-3 type-b expression was detected in 
those four lung cancer cells. So they discussed the possibility that minor promoter (type-b) was utilized 
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for the expression in a tissue specific manner, as seen in dual promoter of APC gene. 
In this study, we examined the DNA methylation of REIC/Dkk-3 type-a in various kinds of 
cancers by quantitative combined bisulfite restriction analysis (qCOBRA) and investigated the correlation 
between the REIC/Dkk-3 type-a methylation and REIC/Dkk-3 type-a expression. The qCOBRA assay can 
provide more reliable results because the conventional methylation-sensitive restriction enzyme assay that 
Kobayashi et al. (2002) performed was recently known to be prone to false positive results due to 
spurious incomplete digestion (Xinog et al. 1997). We also analyzed the correlation between REIC/Dkk-3 
type-a and type-b expression in various cancer cell lines. Furthermore, we examined the correlation 
between REIC/Dkk-3 type-a methylation and the clinicopathological features of primary tumors. 
 
Materials and Methods 
Clinical samples and cell culture 
Surgically resected specimens of 37 primary breast cancers, 42 primary NSCLCs, 21 primary gastric 
cancers, 20 primary colon cancers and 7 MPMs were obtained from Okayama University Hospital 
(Okayama, Japan), 6 MPMs were obtained from Okayama Rousai Hospital (Okayama, Japan), 5 MPMs 
were obtained from National Sanyo Hospital (Yamaguchi, Japan), 27 MPMs were obtained from 
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Karmanos Cancer Center (MI). Ten corresponding non-malignant breast tissues and 10 non-malignant 
lung tissues were also examined. All tissues were frozen with the liquid nitrogen immediately after 
surgery and were stored at -80°C until extraction of DNA. Institutional Review Board permission and 
informed consent were obtained for all cases. 
Seven breast cancer cell lines (HCC70, HCC1599, HCC1806, MDA-MB-231, MDA-MB-361, 
MCF7 and ZR75-1) and 11 lung cancer cell lines (NCI-H23, NCI-H44, NCI-H125, NCI-H157, 
NCI-H1299, NCI-H1819, NCI-H1963, NCI-H1975, NCI-H2009, NCI-H358 and A549), 4 MPM cell 
lines (NCI-H2052, NCI-H2373, NCI-H2452, NCI-H290), 6 prostate cancer cell lines (PC3, LNCap-FGC, 
Du145, Caki-1, Caki-2 and KPK) were examined in this study. MCF7, ZR-75-1, MDA-MB-231, 
MDA-MB-361 were obtained from Cell Resource Center for Biomedical Research Institute of 
Development Aging and Cancer Tohoku University (Miyagi, Japan). Seven cell lines (HCC70, HCC1599, 
HCC1806, H2052, H2373, H290, H2452) were kind gifts from Adi F. Gazdar (Department of Pathology, 
University of Texas Southwestern Medical Center, Dallas, TX). Six cell lines (PC3, LNCap-FGC, Du145, 
Caki-1, Caki-2, KPK) were kind gifts from the department of urology (Okayama university, Okayama, 
Japan). The other cell lines were obtained from American Type Culture Collection (Manassas, VA). The 
cells were maintained in RPMI-1640 medium (Sigma Chemical Co., Saint Louis, MO) supplemented 
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with 10% FBS and were incubated in 5% CO2.  
DNA extraction and DNA methylation modification 
Genomic DNA was extracted from the surgically resected frozen samples and cultured cells by digestion 
with SDS/proteinase K followed by phenol:chloroform (1:1) extraction and ethanol precipitation. Two µg 
of each DNA was treated with EZ DNA Methylation Kit (ZYMO RESEARCH, Orange, CA), following 
the manufacturer’s instructions and was stored at –20 °C until use. 
Quantitative COBRA Assay 
Nested PCR was carried out using bisulfite-treated DNA followed the restriction enzyme digestion. First 
round touchdown PCR was performed under the following conditions: 95°C for 12 min, 40 cycles of 
94°C 45 sec, annealing temperature between 58°C to 56°C for 1 min, 72°C for 3 min, followed by final 
extension step at 72°C for 7 min in a 25 µl reaction mixture containing with 67 mM Tris-HCl (pH 8.8), 
16.6 mM (NH4)2SO4, 6.7 mm MgCl2, 10 mM β-mercaptoethanol, 1.25mM of each deoxynucleotide 
triphophate (dNTP) mixture, 0.5 µM of each primer, 0.5 unit of HotStar Taq DNA Polymerase (Qiagen, 
Valencia, CA) and 100 ng of bisulfite-treated DNA. Second round touchdown PCR was performed using 
0.4 µl of the first round PCR products as a template under same condition, but 47 cycles. Universal 
methylated DNA and universal unmethylated DNA were used for positive control and negative control, 
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respectively. The location of the CpG dinucleotides in the exon1 and in the 5'-flanking region of 
REIC/Dkk-3 is shown in Fig.1. Primers were designed using Primer Express Software ver.1.0 in the 
promoter region of REIC/Dkk-3 type-a. Primers for the first round PCR were REIC-COBRA-F1 
5’-TGGGTTGTTGTAAGTTTGAAGGT-3’, REIC-COBRA-R1 5’-CTCACCCACCCCRACTAAAC-3’, 
Primers for the second round PCR were as follows: REIC-COBRA-F2 
5’-TGAAGGTTAGATAAGAYGGGTTTAGG-3’, REIC-COBRA-R2 
5’-ACCCACCCCRACTAAACCRAAT-3’. These primers were designed to ensure amplification of both 
methylated and unmethylated forms. Two µl of second PCR products were digested with 3 units of BstUI 
(which restriction site is CGCG) for the restriction fragment length polymorphism analysis. The amplicon 
of second PCR was named RRCOBRA (Region for REIC COBRA) and the 5 restriction sites of BstUI 
are shown in Fig.1. The digested PCR products were visualized on 3% agarose gels stained with ethidium 
bromide. The percentages of digested band were analyzed by NIH ImageJ 1.37V Software 
(http://rsb.info.nih.gov/ij) as described previously (Xiong and Laird 1997). We performed linear 
regression analysis of qCOBRA with nested PCR using serial dilution to examine if qCOBRA with nested 
PCR really reflected % methylation. We diluted unmethylated DNA amplicon with methylated amplicon 
to make serial dilution (% methylated DNA; 0, 10, 20, 30, 50, 70, 80, 90, 100 %) and performed 
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qCOBRA, as described above. 
Bisulfited DNA Sequencing Analysis 
RRCOBRA was cloned into pCR2.1-TOPO Vector using TOPO TA cloning kit (Invitrogen Life 
Technologies, Carlsbad, CA) following manufacturer’s instructions. To determine the methylation status 
in the promoter lesion of REIC/Dkk-3 gene, five breast cancer cell lines (MCF-7, MDA-MB-231, ZR75-1, 
HCC1806 and HCC1599) and a lung cancer cell lines (H1299) were examined. Individual 7 clones from 
each cell line were sequenced using the dGTP BigDye terminator v3.1 Cycle Sequencing Kit with the 
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). 
RNA extraction and Reverse Transcriptional (RT)-PCR 
Total RNA was extracted from cultured cells using RNeasy Mini Kit (Qiagen, Valencia, CA) following 
the manufacturer’s instruction. Oligo(dT)-primed cDNA was synthesized using Super-Script II (Qiagen, 
Valencia, CA) with DNase treatment. RT-PCR was carried out in a 20 µl of reaction mixture with 1xPCR 
buffer, 200 µM of dNTP, 0.3 µM of each primer, 0.5 units of HotStarTag DNA Polymerase and 100 ng of 
cDNA. A touchdown PCR was performed for REIC/Dkk-3 type-a and type-b under the following 
conditions: 95°C for 12 min, 35 cycles of 94°C 30 sec, annealing temperature between 62°C to 58°C for 1 
min, 72°C for 3 min, followed by final extension step at 72°C for 7 min. As an internal control, RT-PCR 
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for GAPDH was carried out under the following conditions: 95°C for 12min, 35 cycles of 94°C for 45 sec, 
55°C for 90 sec, 72°C for 90 sec followed by final extension step at 72°C for 7 min. The primers for 
REIC/Dkk-3 type-a expression were REIC(a)-F 5’-GGGAGCGAGCAGATCCAGT-3’ (exon1a), 
REIC(a)-R 5’-TTTGTCCAGTCTGGTTGTTGGT-3’ (exon3). The primers for REIC/Dkk-3 type-b 
expression were REIC(b)-F 5’-TGGGAGCTATTAGCGTAGAGGAT-3’ (exon1b), REIC(b)-R 
5’-CATTGTGATAGCTGGGAGGTAAG-3’ (exon3). The PCR products were visualized on 2% agarose 
gels stained with ethidium bromide. The bands were analyzed using NIH ImageJ 1.37V Software. The 
expression ratio in each cell line was defined as the ratio of particular sample when compared to those of 
H1299. To confirm the responsibility of DNA methylation for REIC/Dkk-3 silencing, we treated heavily 
methylated cell lines (MDA-MB-231) with 5-Aza-2’-deoxycytidine (5-Aza-CdR) at the concentration of 
5 μM and 8 μM for 6 days with medium changes on days1, 3 and 5. Treated and untreated cells from 
individual triplicate flasks were harvested on day 6 to determine the REIC/Dkk-3 type-a expression using 
RT-PCR. 
ER, PgR and HER2 status in primary breast cancers 
Estrogen receptor (ER), Progesterone receptor (PgR) and HER2 status in primary breast cancers was 
obtained from patient medical records. HER2 positive was defined as a score of 2+ and 3+ by 
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immunohistochemistry. 
Statistical analyses 
The frequencies of REIC/Dkk-3 methylation between two groups were compared using the Fisher's exact 
test or Mann-Whitney’s U test when appropriate. Probability value less than 0.05 was defined as being 
statistically significant. All data was analyzed by JMP9 for Windows (SAS Institute, Cary, NC). 
 
Results 
DNA methylation status in the promoter region of REIC/Dkk-3 type-a 
The result of bisulfite genomic DNA sequencing of RRCOBRA are shown in Fig.1. Each CpG in the 
5’-flanking region and in exon1a was heavily methylated in MCF7, MDA-MB-231 and ZR75-1. The 
CpGs in the 5’-flanking region of exon 1a were lightly to moderately methylated, but the CpGs in exon1a 
were rarely methylated in HCC1806 and HCC1599. In contrast, most of the CpGs were rarely methylated 
in H1299. 
We performed the linear regression analysis using the nested qCOBRA and confirmed the 
quantitative capacity (data not shown). Representative examples of the COBRA assay in breast cancer 
cell lines are shown in Fig. 2a. The percentages of REIC/Dkk-3 type-a methylation were calculated by 
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qCOBRA in each cell line and primary tumor (Fig. 2b and 2c, respectively) and summarized in Table1. 
We decided the samples with more than 10% of digested bands as methylation positive in this study. 
Aberrant methylation was detected in 7 of the 7 (100%) breast cancer cell lines and 16 of the 37 (43.2%) 
primary breast cancers; 5 of the 11 (45.4%) lung cancer cell lines and 11 of the 42 (26.2%) primary lung 
cancers; 0 of 4 (0%) in MPM cell lines and 7 of the 27 (25.9%) USA primary MPMs; 7 of the 18 (38.9%) 
Japanese primary MPMs, 8 of the 21 (38.1%) primary gastric cancers; and 10 of the 20 (50.0%) primary 
colon cancers. REIC/Dkk-3 methylation was not detected in 10 normal breast tissues and 10 normal lung 
tissues (data not shown). The methylation of REIC/Dkk-3 type-a in the breast cancer cell lines was more 
frequent than that in the lung, MPM and prostate cancer cell lines (p = 0.02, p = 0.01 and p = 0.04, 
respectively). However, no significant differences in methylation were observed among the primary 
breast, lung, MPMs, gastric and colon cancers (Fig.2c). The results of qCOBRA in five breast cancer cell 
lines and a lung cancer cell line (H1299) were corresponded with the results of bisulfite sequencing. 
REIC/Dkk-3 mRNA expression in cell lines and correlation with qCOBRA assay. 
Representative example of RT-PCR for REIC/Dkk-3 type-a and type-b in the breast cancer cell lines was 
shown in Fig.2d. Expression of REIC/Dkk-3 type-a was only detected in HCC1599 and HCC1806 cells, 
which rarely to moderately harbored REIC/Dkk-3 methylation. Expression of REIC/Dkk-3 type-b was also 
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detected in HCC1599 and HCC1806 cells. The results of expression of REIC/Dkk-3 type-a and type-b in 
all cell lines (n=28) were summarized in Table 2. There was a correlation between the expression of 
REIC/Dkk-3 type-a and type-b (p<0.01). The relative expressions of REIC/Dkk-3 type-a mRNA and the 
percentages of REIC/Dkk-3 type-a methylation are shown in Fig.3. The expression of REIC/Dkk-3 type-a 
and REIC/Dkk-3 type-a methylation was inversely correlated in the cell lines that were examined 
(p<0.01). To confirm that methylation was responsible for the gene silencing, heavily methylated 
MDA-MB-231 cells were treated with 5-Aza-CdR. REIC/Dkk-3 type-a mRNA expression was restored by 
the treatment of 5-Aza-CdR in a dose-dependent manner (Fig.4).  
REIC/Dkk-3 methylation and clinicopathological correlation. 
We next examined the relationships between the REIC/Dkk-3 methylation status and the 
clinicopathological factors described in Table 3. For the breast cancers, we observed that ER-positive 
cases were more common in the methylated group than in the nonmethylated group (p=0.03). No 
significant relationships between REIC/Dkk-3 methylation and the other clinicopathological factors were 
observed. 
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Discussion 
In this study, we demonstrated that arbitrary CpG methylation in REIC/Dkk-3 type-a promoter 
region was frequently observed in solid malignancies. Regarding qCOBRA in this study, we confirmed 
the accuracy of this assay by linear regression analysis because we performed nested PCR. We decided 
the samples with more than 10% of digested bands as methylation positive to maintain compatibility with 
conventional COBRA assay, as we could distinguish 10% of digested band on the agarose gel 
electrophoresis. Collolla et al. (2003) also used a 10% threshold to declare methylation when compared 
qCOBRA with pyrosequencing methylation analysis. So a 10% threshold seems to be reasonable criteria 
to distinguish methylation positive. We examined cell lines using qCOBRA assay, and the accuracy of the 
qCOBRA was also confirmed by bisulfate genomic DNA sequencing and linear regression analysis.  
The REIC/Dkk-3 type-a methylation, that was determined using qCOBRA assay, revealed to be inversely 
correlated with the REIC/Dkk-3 type-a mRNA expression among the cell lines (p<0.01), and the 
restoration of REIC/Dkk-3 type-a expression by 5-Aza-CdR treatment was observed in a REIC/Dkk-3 
type-a methylated cell line. These results indicate that DNA methylation of REIC/Dkk-3 type-a was 
responsible for silencing REIC/Dkk-3 type-a expression. As reported previously, we confirmed that there 
was a correlation between REIC/Dkk-3 type-a expression and type-b expression in the cell lines that we 
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examined (p<0.01). Discrepancy of the expression level between REIC/Dkk-3 type-a and type-b was 
observed in lung cancer cell lines, although the expressions of REIC/Dkk-3 type-a were completely 
corresponded with the expression of REIC/Dkk-3 type-b in other cell lines, indicating that REIC/Dkk-3 
type-b might be utilized for the expression in a tissue specific manner, as Kobayashi et al. (2002) 
described. 
 Among the cancers that were examined, REIC/Dkk-3 type-a methylation was more frequently 
detected in breast cancer cell lines, although moderate methylation was also observed in other cancers. A 
previous report showed that the introduction of REIC/Dkk-3 into some breast cancer cells had an 
anti-tumor effect (Kawasaki et al. 2009). In addition, the introduction of REIC/Dkk-3 into cancer cells 
had a direct effect on the induction of apoptosis and an indirect effect on the activation of tumor immunity 
in NK cells through the up-regulation of IL-7 (Sakaguchi et al. 2009). Furthermore, REIC/Dkk-3 induces 
the differentiation of human CD14+ monocytes into a novel cell type, resembling immature dendritic 
cells generated with IL-4 and GM-CSF (Watanabe et al. 2009). These findings support the possible utility 
of REIC/Dkk-3 gene therapy for not only breast cancers but also a broad range of human malignancies. 
Indeed, REIC/Dkk-3 gene therapy is ongoing for prostate cancer 
(http://clinicaltrials.gov/ct2/show/NCT01197209).  
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Regarding the clinicopathological factors, we found that ER-positive breast cancer was more 
common in the methylated group than in the non-methylated group in the present study. In contrast, Veeck 
et al. (2009) reported that REIC/Dkk-3 methylation was not correlated with the ER and PgR statuses. In 
other cancers, no significant relationship was observed between the REIC/Dkk-3 methylation status and 
any of the clinicopathological factors that were examined. Previous study has shown that REIC/Dkk-3 
methylation was associated with poor survival in primary breast cancers (Veeck et al. 2009). We could not 
compare these results directly because they examined the REIC/Dkk-3 type-b methylation, which has a 
lower promoter activity than that of REIC/Dkk-3 type-a. In addition, the number of cases in this study 
may have been too small for the survival analysis, since the primary purpose of this study was to detect 
REIC/Dkk-3 type-a methylation and to examine the correlation between methylation and expression. In 
lung cancer, reduced expression of REIC/Dkk-3 was previously shown to be frequent in poorly 
differentiated adenocarcinoma and squamous cell carcinoma (Nozaki et al. 2001). Further investigations 
are needed to determine the clinicopathological impact of REIC/Dkk-3 type-a methylation. 
In conclusion, we found that the promoter region of REIC/Dkk-3 type-a was frequently 
methylated in breast, lung, gastric, colon, prostate cancers and MPMs. REIC/Dkk-3 type-a methylation 
and REIC/Dkk-3 type-a mRNA expression were inversely correlated in the cell lines that were examined. 
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Our results suggest that REIC/Dkk-3 type-a methylation is an important mechanism in the pathogenesis of 
various types of malignancies. Since gene therapy using REIC/Dkk-3 expressing adenovirus vectors is 
currently on going for the treatment of prostate cancer, similar therapeutic modalities may be applicable 
for other types of cancers.    
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Table 1 Rate of REIC/Dkk3 methylation in each human cancer by quantitative COBRA assay 
Organ 
Number of REIC/Dkk3 methylated sample (%) 
Cell lines Primary tumors 
Breast cancer 7 of 7 (100%) 16 of 37 (43.2%) 
Lung cancer 5 of 11 (45.4%) 11 of 42 (26.2%) 
Malignant pleural mesothelioma 
(USA) 
(Japanese) 
0 of 4 (0%) 
ND 
 
7 of 27 (25.9%) 
7 of 18 (38.9%) 
Gastric cancer ND 8 of 21 (38.1%) 
Colon cancer ND 10 of 20 (50.0%) 
Prostate cancer 3 of 6 (50%) ND 
ND: not determined 
 
 
 
 
 
 24 
Table 2 Expression of REIC/Dkk-3 type-a and type-b in various cancer cells 
Organ 
mRNA expression 
type-a type-b 
Breast cancers 
HCC70 - - 
HCC1599 + + 
HCC1806 + + 
MDA-MB-231 - - 
MDA-MB-361 - - 
MCF7 - - 
ZR75-1 - - 
Lung cancers 
H23 + - 
H44 - - 
H125 + - 
H157 + + 
H1299 + + 
H1819 + + 
H1963 + + 
H1975 - + 
H2009 - - 
H358 - - 
A549 + + 
MPMs 
H2052 + + 
H2373 + + 
H2452 - - 
H290 + + 
Prostate cancers 
Caki-1 + + 
Caki-2 + + 
Du145 + + 
KPK + + 
LNCapFGC - - 
PC3 - - 
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Table 3 Clinicopathological factors and REIC/Dkk-3 methylation in various primary cancers 
A. primary breast cancers 
Variables Number of methylation 
positive samples (%) 
Total (n=38) 16 (39) 
Age  
<65 (n=32) 14 (44) 
65≤ (n= 6) 1 (17) 
Histology  
papillotubular (n=8) 2 (25) 
Solid-tubular (n=11) 4 (36) 
Scirrhous (n=17) 9 (53) 
Others (n=2) 0 
T categories  
1 (n=11) 6 (55) 
2 (n=16) 5 (31) 
3 (n=3) 1 (33) 
4 (n=8) 3 (38) 
N categories  
0 (n=15) 6 (40) 
1 (n=23) 9 (39) 
M categories  
0 (n=36) 14 (23) 
1 (n=2) 1 (50) 
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Stage  
I (n=9) 5 (56) 
II (n=15) 5 (33) 
III (n=12) 4 (33) 
IV (n=2) 1 (50) 
Estrogen receptor *  
Positive (n=19)  11 (58) 
Negative (n=18) 4 (22) 
Progesterone receptor  
Positive (n=18) 9 (50) 
Negative (n=15) 6 (40) 
HER2 status  
Positive (n=11) 3 (27) 
Negative (n=19) 10 (53) 
*: p<0.05 
 
B. Primary lung cancers 
Variables Number of methylation 
positive samples (%) 
Total (n=41) 11 (27) 
Age  
<65 (n=17) 3 (18) 
65≤ (n=24) 8 (33) 
Histology  
 Adenocarcinoma (n=27) 7 (26) 
Squamous cell 
 carcinoma (n=14) 
4 (29) 
T categories  
1 (n=27) 7 (26) 
 27 
2 (n=12) 4 (33) 
       3 (n=0) 0 
       4 (n=2) 0 
N categories  
0 (n=29) 8 (28) 
1 (n=10) 2 (20) 
M categories   
0 (n=39) 11 (28) 
1 (n=2) 0 
Stage  
I (n=28) 8 (29) 
II (n=4) 1 (25) 
III (n=7) 1 (14) 
IV (n=2) 0 
 
 
C. Primary gastric cancers 
Variables Number of methylation 
positive samples (%) 
Total (n=21) 8 (38) 
Age  
<65 (n=10) 5 (50) 
65≤ (n=11) 3 (27) 
Histology  
Intestinal (n=10) 5 (50) 
Diffuse (n=11) 3 (27) 
T categories  
1 (n=3) 1 (55) 
2 (n=8) 4 (50) 
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3 (n=7) 2 (29) 
4 (n=3) 0 
N categories  
0 (n=7) 4 (57) 
1≤ (n=14) 4 (29) 
Stage  
I (n=6) 4 (67) 
II (n=3) 1 (33) 
       III (n=5) 3 (60) 
IV (n=7) 0 
 
D. Primary colon cancers 
Variables Number of methylation 
positive samples (%) 
Total (n=20) 10 (50) 
Age  
<65 (n=9) 5 (56) 
65≤ (n=11) 5 (46) 
Histology  
Well (n=5) 1 (20) 
Moderately (n=11) 6 (55) 
Poorly (n=3) 2 (67) 
Others (n=1) 1 (100) 
T categories  
1 (n=2) 1 (50) 
2 (n=0) 0 
3 (n=14) 6 (43) 
4 (n=3) 3 (100) 
N categories  
0 (n=8) 4 (50) 
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1≤ (n=12) 6 (50) 
M categories  
0 (n=12) 6 (50) 
1 (n=8) 4 (50) 
Stage  
I (n=3) 2 (67) 
II (n=4) 1 (25) 
III (n=5) 3 (60) 
IV (n=8) 4 (50) 
Location  
Right (n=8)  5 (63) 
Left (n=11) 4 (36) 
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Figures legends 
Fig.1 Map of the 5’-flanking region of REIC/Dkk-3 and the bisulfite genomic DNA sequence 
Upper figure demonstrates the promoter region of REIC/Dkk-3. Gray bars indicate exons 
and the bent arrow indicates the transcription start site (TSS) (+1). Thin vertical lines on the 
horizontal line indicate the sites of CpG dinucleotides. Allow heads indicate the restriction sites of 
BstUI. COBRA primer sets are indicated by pairs of bold arrows. Dark gray bar under the COBRA 
primer sets indicates RRCOBRA. Methylation status of individual subcloned DNA fragments of 
each cell line is shown below. Each circle represents a CpG dinucleotide in 5’-flanking region of 
REIC/Dkk-3 (for -213 to +205 nt). The numbers at the top indicate the CpG dinucleotide in the 
RRCOBRA (from 5’ to 3’). These numbers correspond to those depicted in upper figures. Open 
circle represents non-methylated CpG dinucleotide; Black circle represents methylated CpG 
dinucleotide.  
 
Fig.2 Quantitative COBRA assay 
The results of COBRA assay for REIC/Dkk-3 type-a in breast cancer cell lines were 
shown in Fig.2a. Methylated alleles were fragmented with restriction enzyme modification and 
 31 
unmethylated alleles were uncut. Percentages of digested band in cell lines (Fig.2b) and primary 
tumors (Fig.2c) were quantitated by NIH ImageJ 1.37V software. The horizontal bars indicate the 
average in each group. The mRNA expression of REIC/Dkk-3 type-a and type-b in breast cancer cell 
lines was shown in Fig.2d. PC, universal methylated DNA as positive control; NC, universal 
unmethylated DNA as negative control. 
 
Fig.3 Relative expression of REIC/Dkk-3 type-a mRNA and percentages of REIC/Dkk-3 
methylation in each cell line 
Columns show the relative expression of REIC/Dkk-3 type-a mRNA in each sample. The 
expression ratio was defined as the ratio of particular sample when compared to those of H1299. % 
methylation was calculated by qCOBRA assay.  
 
Fig.4 Restoration of REIC/Dkk-3 type-a mRNA expression in MDA-MB-231 cells 
The effect of 5-Aza-CdR on the restoration of REIC/Dkk-3 type-a mRNA expressions in 
heavily methylated breast cancer cells (MDA-MB-231). REIC/Dkk-3 type-a mRNA was detected by 
RT-PCR. GAPDH was used as an internal control. 
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*Response to reviewer's comments
Click here to download Response to reviewer's comments: Revise JCRCO.doc 
Reviewer #1: Hayashi T et al demonstrated frequent methylation at the promoter region of 
REIC/Dkk-3 in various cancers by using quantitative COBRA and bisulfite sequencing. 
Among them, ER-positive breast cancers were significantly methylated compared with its 
negative ones. Here, the authors focused on Dkk-3 type-a methylation, because it has 
already been shown that the promoter activity of type-a was much stronger than that of 
type-b (Kobayashi K, Gene, 2002). Nevertheless, it has been reported that methylation of 
Dkk-3 type-b was detected in various cancers (Introduction, page 5, 2nd paragraph). 
Therefore, additional data are necessary in order to show the importance of Dkk-3 type-a 
in cancers. 
Comments: 
1)  The authors should study methylation and expression of Dkk-3 type-a in primary tissues, 
and analyze whether or not these show inverse correlation in cancer tissues like cancer cell 
lines. It is also important to compare the methylation status between type-a and -b in 
cancers. 
2)  Nested PCR with 40 cycles was used for COBRA analysis in this study. It is not likely 
that such conditions really reflect % methylation in cancers. Many data on COBRA consist 
of standard PCR but not of nested PCR. The authors should perform linear regression 
analysis using the nested PCR with % control DNA (% methylation: 0- 100%), which was 
shown in the previous report (Xiong and Laird 1997). 
3)  In Figure 4 and page 10, the authors should indicate the concentration of 5-Aza-CdR. 
It is widely used 1-10 μM as a final concentration. 
4)  No information on 27 mesotheliomas from USA (Figure 2d) was seen in the text. 
 
Response: 
1. We usually look up cell lines to examine the relation between DNA methylation and 
mRNA expression (Tomii et al. Int.J.Cancer 2006), because cancerous tissue sometimes 
contain normal counterparts (stroma, lymphocyte, etc) or mRNA degradation may occur 
even in frozen samples. We have examined the relation between REIC/Dkk-3 methylation 
and REIC/Dkk-3 mRNA expression in cell lines and showed the inverse correlation in our 
manuscript. 
As for the importance of REIC/Dkk-3 type-a, Kobayashi et al.(Gene 282, 151-158, 
2002) described not only the promoter activity of type-a was much stronger than that of 
type-b, but also they confirmed major transcript was type-a isoform in the various cancer 
cells that they tested. They also suggested hyper-methylation of major promoter (type-a) 
was major mechanism for the down-regulation of REIC/Dkk-3 expression. Further more, 
they described type-a methylation was accompanied with the type-b methylation in most 
case except four lung cancer cells that they tested. REIC/Dkk-3 expression was detected in 
those four lung cancers, regardless those four lung cancers have type-b hypermethylation. 
So they discussed the possibility that minor promoter (type-b) was utilized for the 
expression in a tissue specific manner, as seen in dual promoters in APC gene.  
But there is some weakness in the method for detecting DNA methylation in their 
paper. They examined DNA methylation by methylation-specific restriction enzyme that 
was no longer in use, recently. Take into consideration these results, it seems to be 
reasonable to examine the major promoter (type-a) methylation by quantitative COBRA in 
various cancers. We can provide reliable methylation status of REIC/Dkk-3 type-a. 
We added the explanation why we focused on REIC/Dkk-3 type-a in page 5 L11-16. 
 
2. We agreed with the comment. We decided to use 10% threshold, because we could 
recognize 10% of digested bands on the agarose gel electrophoresis and we assume those 
sample are positive in conventional COBRA assay. On the other hand, the digested bands 
less than 10% are so faint that we can’t easily recognize those bands on agarose gel 
electrophoresis. 10% of digested bands seem to be reasonable criteria to maintain 
compatibility with conventional COBRA assay. We could observe the inversely correlation 
between REIC/Dkk-3 methylation and REIC/Dkk-3 expression using this criteria. To 
support this idea, Collella et al. (BioTechniques 2003) described that qCOBRA and 
pyrosequencing methylation analysis (PyroMethA) always gave concordant calls for the 
methylation status when a 10% threshold to declare methylation was used. 
We performed the linear regression analysis using the nested qCOBRA and 
confirmed the quantitative capability as shown below. 
We added the methodology of linear regression analysis in page 9. 
We added “we performed the linear regression analysis using nested qCOBRA and 
confirmed the quantitative capacity” in page 12.  
 
%methylated DNA % unmethylated DNA   qCOBRA(% digested bands) 
   100 0 99.7% 
    90 10 84.7% 
    80 20 75.2% 
    70 30 69.2% 
    50 50 39.4% 
    30 70 33.2% 
    20 80 26.9% 
    10 90 17.9% 
     0 100  2.5% 
 
3. We indicated the concentration of 5-Aza-CdR in Figure 4 and page 11. 
4. We described the information about 27 mesotheliomas from USA (page 6, page 12 and 
Table1). 
 
 
Reviewer #2: In this manuscript, Hayashi et al. analyzed the DNA methylation status of the 
promoter region of REIC/Dkk-3 type-a in various malignancies, including breast cancers, 
non-small cell lung cancer (NSCLCs), gastric cancers and colorectal cancers, and 
malignant pleural mesotheliomas. The authors describe i) that the methylation status of 
REIC/Dkk-3 type-a was varied among cancers, ii) that the methylation status was inversely 
correlated with REIC/Dkk-3 type-a expression, and iii) that estrogen receptor (ER) 
positive breast cancers were significantly methylated compared with ER negative breast 
cancers. 
REIC/Dkk-3 has two alternative tissue-specific promoters, type-a and type-b, and the 
silencing of REIC/Dkk-3 and hypermethylation of REIC/Dkk-3 type-b promoter have 
already been reported in a variety of malignancies. Thus, in this study, the authors 
analyzed methylation status of type-a promoter using other types of malignancies. This is a 
potentially important study to understand the silencing mechanism of REIC/Dkk-3 more 
deeply. However, the authors should address the following concerns to make their data 
solid. 
Major Comments: 
1. The authors should investigate which is the major transcript of REIC/Dkk-3, type-a or 
type-b, in normal counterparts of cancers analyzed in this study, or in cancer cell lines 
expressing REIC/Dkk-3. The authors claimed that the reason why they focused on 
REIC/Dkk-3 type-a promoter was that a previous report showed that promoter activity of 
REIC/Dkk-3 type-a was stronger than that of type-b in 293 cells (Kobayashi et al., 2002).  
However, it is known that the promoter activity is dependent on cell types used for 
promoter assay, and to reveal the major transcript in normal cells is important for the 
decision of target promoter for DNA methylation analysis. 
2. The novelties of this study should be clarified. The previous study already has reported 
DNA methylation status of REIC/Dkk-3 type-a in gastric cancers and NSCLC (Kobayashi 
et al., 2002). The authors should clearly describe which cancer types are newly analyzed in 
this study. 
3. The authors should describe the reason why they used 10% as the criteria for 
methylation-positive cancers. The criteria should be determined for each cancer types 
because the contents of stroma are different among cancer types. 
4. The authors should investigate the association of DNA methylation status and HER-2 
amplification for breast cancers because HER-2 amplification is an important factor of 
breast cancer characteristics, and HER2 amplification is reported to be associated with 
frequent DNA methylation at multiple CpG islands (Terada et al, 2009). 
Minor Comments: 
1. The authors should add a photo of the positive control, such as GAPDH mRNA, to 
Figure 4. 
 
Response; 
1. With regard to cancers, Kobayashi et al. (2002) already described main promoter was 
type-a and the methylation of main promoter is the major mechanism for down-regulation 
of REIC/Dkk-3 expression. We commented the reason why we had focused on major 
promoter (type-a) in the response to reviewer1 as discussed above. 
With the regard to the REIC expression (type-a and b) in primary tumors and normal 
counterparts, we won’t examine the mRNA in frozen samples, because cancerous tissue 
sometimes contain normal counterparts (stroma, lymphocyte, etc) or mRNA degradation 
may occur even in frozen samples. 
 
2. Kobayashi et al. (2002) described the REIC methylation in mainly lung and gastric 
cancer cells, but there is a weakness in their study, because they examined DNA 
methylation by methylation-specific restriction enzyme that was no longer in use, recently. 
This manuscript will be the first paper that quantified the REIC/Dkk-3 main promoter 
(type-a) methylation by reliable qCOBRA in many cell lines and primary cancers, such as 
breast, lung, gastric, colorectal cancers and pleural mesothelioma. There is no paper 
described the REIC/Dkk-3 methylation in mesotheliomas. Those are novelties of our study.  
 
3. We responded why we used a 10% threshold in our manuscript, as noted above. We 
could not detect any REIC/Dkk-3 type-a methylation in corresponding 10 non-malignant 
breast tissues and 10 non-malignant lung tissues. 
 
4. As reviewer says, it is true that HER-2 amplification is an important factor in breast 
cancers. But we are focused on the relation between REIC/Dkk-3 type-a methylation and its 
mRNA expression. We think that REIC/Dkk-3 methylation does not directly involve in 
HER-2 amplification. 
 
Minor Comments; 
1. We add internal control (GAPDH) to Figure 4. 
Reviewer #2:        Hayashi et al. addressed this Reviewer's comments as in 
the "Responses to reviewers".  However, some responses seem to have failed 
to address the concerns appropriately.  At least, the authors should reflect 
their responses in the revised manuscript to help the readers of Journal of 
Cancer Research and Clinical Oncology.     Comments:   1. This Reviewer 
commented that expression of REIC/Dkk-3 type-b should be analyzed, in 
addition to that of type-a, to identify the major transcript in the samples 
analyzed in this study.  Even if type-a was the main promoter of REIC/Dkk-3 
in NIH/3T3 cells (Kobayashi et al., 2002), there is a possibility that the minor 
promoter (type-b) is used in a tissue-specific manner, as the authors 
mentioned in Introduction (page 5, ll. 16).  The authors must analyze 
expression of type-b in their own samples.  2. The authors should clearly 
describe the novelty of this study in the revised manuscript, not only in their 
response to the Reviewer.  3. The reason why the authors used a threshold of 
10% for methylation-positive samples should be added to Materials and 
Methods.  4. As for their reply to my recommendation to analyze the 
association between REIC/Dkk-3 type-a methylation status and HER-2 
amplification status, the authors replied, "we are focused on the relation 
between REIC/Dkk-3 type-a methylation and its mRNA 
expression".  However, the authors showed "REIC/Dkk-3 methylation and 
clinicopathological correlation" in Result (Page 13, ll 12-15).  Since HER-2 
amplification status is one of the important clinicopathological characteristics, 
the authors should analyze the association between REIC/Dkk-3 type-a 
methylation status and HER-2 amplification status. 
 
Response; 
1. We examined the expression of REIC/Dkk-3 type-b in breast, lung, malignant pleural 
mesothelioma, prostate cancer cells and described the results in Table 2 and Fig.2d. The 
expression of REIC/Dkk-3 type-a was corresponded with REIC/Dkk-3 type-b (p<0.01) in all 
types of cell lines but some discrepancies in lung cell lines. 
We added the primer information for REIC/Dkk-3 type-b in page11 L9-11. 
We added the result and discussion for the expression of REIC/Dkk-3 type-a with type-b in 
page14 L5-8, page16 L3-9. 
*Response to reviewer's comments
Click here to download Response to reviewer's comments: Response 2012-1-10.doc 
We also made some modification in abstract. 
 
2. To strengthen the novelty of this study, we added “The qCOBRA assay can provide more 
reliable results because the conventional methylation-sensitive restriction enzyme assay that 
Kobayashi et al. (2002) performed was recently known to be prone to false positive 
results due to spurious incomplete digestion (Xinog Z et al. 1997). We also analyzed the 
correlation between REIC/Dkk-3 type-a and type-b expression in various cancer cell 
lines.” in page 6 L9-13. 
 
3. We added the method for linear regression analysis in page10 L2-6. We also discussed the 
validity of 10% threshold in page15 L7-13. 
 
 4. We added HER2 status in primary breast cancers by immunohistochemistry. We add HER2 
status in Table 3A. However, there was no correlation between HER2 status and REIC/Dkk-3 
methylation. We added the methodology in page12 L3-6. 
